ReviewCurrent urology reports2025
The Role of PSMA PET Imaging in Prostate Cancer: Current Applications and Future Directions.
Review in Current urology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging.European journal of nuclear medicine and molecular imaging · 2026Article
- A computer-aided diagnosis tool in prostate cancer patients with biochemical recurrence using 18F-PSMA PET/CT imaging.Medical physics · 2026Article
- Prostate Cancer Biomarkers with a Focus on Galectin-3: Emerging Clinical and Therapeutic Implications.Current oncology (Toronto, Ont.) · 2026Review
- Article
- The Crosstalk Mechanisms Between Ferroptosis and Pyroptosis and Their Applications in Diseases: From Molecular Networks to Clinical Strategies.Journal of cellular and molecular medicine · 2026Review
- Aortic Calcifications Mimicking Lymph Nodes onMolecular imaging and radionuclide therapy · 2026Article
- Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).Theranostics · 2026Review
- A PSMA-targeted dextran-based conjugate eradicates PSMA-overexpressing prostate tumors while abolishing cabazitaxel toxicity.Theranostics · 2026Article
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Establishing 18F-PSMA-1007 Production in Armenia: Radiosynthesis and Comprehensive Quality Control.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewProstate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging has revolutionized prostate cancer detection and management. This review aims to evaluate the latest advancements in PSMA PET imaging, assess its clinical applications in various disease stages, and compare it to conventional imaging techniques. We sought to determine how PSMA PET impacts clinical decision-making, treatment strategies, and patient outcomes, with a focus on its expanding role in precision oncology. RECENT
findingsRecent studies have demonstrated that PSMA PET exhibits superior sensitivity and specificity in detecting prostate cancer metastases, particularly in cases of biochemical recurrence and early-stage disease. The advent of radiolabeled PSMA ligands, such as 68Ga-PSMA-11 and 18 F-DCFPyL, has led to improved diagnostic accuracy. Furthermore, PSMA-targeted radioligand therapies (e.g., 177Lu-PSMA-617) show promising results in metastatic castration-resistant prostate cancer (mCRPC), offering a novel therapeutic avenue. Studies have also highlighted the role of PSMA PET in refining treatment plans, including guiding surgery and radiotherapy. PSMA PET imaging represents a paradigm shift in prostate cancer diagnostics, staging, and treatment monitoring. It has led to earlier and more accurate detection of metastases, significantly altering management strategies. The growing body of evidence supports its integration into standard-of-care protocols, with ongoing research focusing on optimizing its therapeutic applications. Future studies should explore cost-effectiveness, accessibility, and potential synergies with emerging systemic therapies to further enhance patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.